Tiziana New Quantitative PET Imaging Data on Foralumab in MS

  Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” that will be presented during the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session at the Annual Meeting of the American Academy of Neurology, to be held April 13-18, 2024 in Denver, Colorado.

https://www.biospace.com/article/releases/tiziana-life-sciences-announces-platform-presentation-of-new-quantitative-pet-imaging-data-on-foralumab-at-the-annual-meeting-of-the-american-academy-of-neurology/